There are currently 1248 clinical trials in Nashville, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University and Sarah Cannon Research Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults
NCT05615220
Recruiting
This Phase 3 multicenter study evaluates the maintenance of efficacy, safety and tolerability of ecopipam tablets in children, adolescents and adults in the treatment of Tourette's Disorder (TD). The study includes an open-label period followed by double-blind, placebo-controlled, randomized withdrawal period.
Gender:
All
Ages:
6 years and above
Trial Updated:
06/18/2024
Locations: Access Clinical Trials, Inc., Nashville, Tennessee +1 locations
Conditions: Tourette Disorder
Register for Updates
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
NCT05652868
Recruiting
This is a Phase I open label multi-center study to evaluate the safety, tolerability, pharmacokinetics and preliminary effectiveness of the investigational drug MYTX-011 in patients with locally advanced, recurrent or metastatic NSCLC. MYTX-011 is in a class of medications called antibody drug conjugates (ADCs). MYTX-011 is composed of a pH-dependent anti-cMET antibody and the potent antimicrotubule drug monomethyl auristatin E (MMAE).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: KisMET-01 Clinical Site, Nashville, Tennessee
Conditions: NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
Register for Updates
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
NCT06150157
Recruiting
The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D[s]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s), in part 2 (Cohort Expansion).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Sarah Cannon Cancer Institute, Nashville, Tennessee
Conditions: Myeloproliferative Disorders, Essential Thrombocythemia, Neoplasms, Myelofibrosis
Register for Updates
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957
Recruiting
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Ascension Saint Thomas West Hospital, Nashville, Tennessee +1 locations
Conditions: Acute Coronary Syndrome
Register for Updates
Pulsed Field Ablation (PFA) Versus Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation
NCT06096337
Recruiting
The purpose of this study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation treatment for subjects with persistent atrial fibrillation as compared to subjects who received an initial treatment with anti-arrhythmic drugs.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Persistent Atrial Fibrillation
Register for Updates
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
NCT03706833
Recruiting
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Centennial Medical Center, Nashville, Tennessee +2 locations
Conditions: Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
Register for Updates
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL
NCT03960840
Recruiting
This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (3L+ DLBCL), adult acute lymphoblastic leukemia (ALL) and 1st Line High Risk Large B-Cell Lymphoma (1L HR LBCL).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Sarah Cannon Research Institute Drug Ship - 4, Nashville, Tennessee +1 locations
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Register for Updates
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
NCT05316155
Recruiting
The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D[s]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and preliminary clinical activity at the RP2D.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Urology Associates, Nashville, Tennessee
Conditions: Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor
Register for Updates
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
NCT05710848
Recruiting
This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Urology Associates, P.C., Nashville, Tennessee
Conditions: Non-muscle-invasive Bladder Cancer
Register for Updates
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
NCT05787821
Recruiting
The main objective of the study is to evaluate the safety, performance and clinical benefits of the Persona implant and its instrumentation in primary total knee arthroplasty
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Southern Joint Replacement Institute, Nashville, Tennessee
Conditions: Knee Pain Chronic, Osteoarthritis, Knee, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Varus Deformity, Valgus Deformity, Flexion Deformity of Knee, Avascular Necrosis
Register for Updates
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
NCT04919512
Recruiting
The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Urology Associates, Nashville, Tennessee
Conditions: Urinary Bladder Neoplasms
Register for Updates
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623
Recruiting
The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without concomitant high-grade Ta or T1 papillary disease; and disease-free survival (DFS) in participants treated with TAR-200 alone with papillary disease only (Cohort 4).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Urology Associates, PC, Nashville, Tennessee +1 locations
Conditions: Urinary Bladder Neoplasms
Register for Updates